Amyloid imaging using fluorine-19 magnetic resonance imaging (19F-MRI)
2016; Elsevier BV; Volume: 30; Linguagem: Inglês
10.1016/j.arr.2015.12.008
ISSN1872-9649
AutoresIkuo Tooyama, Daijiro Yanagisawa, Hiroyasu Taguchi, Tomoko Kato, Koichi Hirao, Nobuaki Shirai, Takayuki Sogabe, Nor Faeizah Ibrahim, Toshiro Inubushi, Shigehiro Morikawa,
Tópico(s)Advanced Neuroimaging Techniques and Applications
ResumoThe formation of senile plaques followed by the deposition of amyloid-β is the earliest pathological change in Alzheimer's disease. Thus, the detection of senile plaques remains the most important early diagnostic indicator of Alzheimer's disease. Amyloid imaging is a noninvasive technique for visualizing senile plaques in the brains of Alzheimer's patients using positron emission tomography (PET) or magnetic resonance imaging (MRI). Because fluorine-19 ((19)F) displays an intense nuclear magnetic resonance signal and is almost non-existent in the body, targets are detected with a higher signal-to-noise ratio using appropriate fluorinated contrast agents. The recent introduction of high-field MRI allows us to detect amyloid depositions in the brain of living mouse using (19)F-MRI. So far, at least three probes have been reported to detect amyloid deposition in the brain of transgenic mouse models of Alzheimer's disease; (E,E)-1-fluoro-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB), 1,7-bis(4'-hydroxy-3'-trifluoromethoxyphenyl)-4-methoxycarbonylethyl-1,6-heptadiene3,5-dione (FMeC1, Shiga-Y5) and 6-(3',6',9',15',18',21'-heptaoxa-23',23',23'-trifluorotricosanyloxy)-2-(4'-dimethylaminostyryl)benzoxazole (XP7, Shiga-X22). This review presents the recent advances in amyloid imaging using (19)F-MRI, including our own studies.
Referência(s)